Our Fight Against Cancer
Kintara Therapeutics is dedicated to the development of novel solid tumor cancer therapies for patients with unmet medical needs.
Kintara Therapeutics has teamed up with outstanding academic and clinical research institutions from around the world to support the development of our novel cancer therapies.
A Pipeline of Breakthrough Cancer Therapeutics
REM-001 is a second generation photosensitizer drug possessing multiple advantages over earlier generation PDT compounds.
REM-001’s indications include:
- Cutaneous Metastatic Breast Cancer
- Recurrent Basal Cell Carcinoma Nevus Syndrome
- Hemodialysis Arteriovenous (AV) Access
Current Clinical Trial
REM-001 Therapy for the treatment of serious cutaneous oncology indications.
This is an open-label, single cohort study to confirm dose, assessments and timing of response, to support future studies. The primary objective of the trial is to evaluate cutaneous tumor response within total target treatment field to REM-001 therapy assessed using standardized digital photography.
Our Platform Strategy:
Unleashing the Potential of Biology
Our platform strategy is built on a robust understanding of cancer biology. We use modern approaches in our laboratory studies to determine where we can solve problems in the treatment of drug and immune resistant cancer.
Our team has identified niches in the continuum of care where our therapeutic may address an unmet need. By showing that our treatments are active where others fail, we can implement clinical studies to demonstrate that our therapies may have the ability to improve patient outcomes.
Partnering with Respected Research Centers Around the Globe
Our collaborations with leading academic institutions play an important role in our approach to advancing research and development. Find out more about how we work with top institutions across the world.
Backed by Years of Experience
Our strong leadership team at Kintara Therapeutics possesses a wealth of expertise in the fields of drug discovery and development and translational cancer biology. The team brings a proven track record of successful product development and commercialization.
